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PCoronary Artery Disease
Characteristics, Management, and Outcomes of 5,557
Patients Age >90 Years With Acute Coronary Syndromes
Results From the CRUSADE Initiative
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Objectives The goal of this work was to explore the treatment and outcomes of patients with non–ST-segment elevation
acute coronary syndromes (NSTE-ACS) age 90 years.
Background The elderly are often excluded from clinical trials of NSTE-ACS and are underrepresented in clinical registries.
Methods We used data from the CRUSADE registry to study 5,557 patients with NSTE-ACS age 90 years and compared
their baseline characteristics, treatment patterns, and in-hospital outcomes with a cohort age 75 to 89 years
(n  46,270).
Results Although both groups had much in common, compared with the younger elderly, the older elderly were less
likely to be diabetic, smokers, or obese. Among patients without contraindications, the older elderly were less
likely to receive glycoprotein IIb/IIIa inhibitors and statins during the first 24 h and were less likely to undergo
cardiac catheterization within 48 h. The older elderly were more likely to die (12.0% vs. 7.8%) and experienced
more frequent adverse events (26.8% vs. 21.3%) during the hospitalization—differences that persisted after ad-
justment for baseline patient and hospital characteristics. Increasing adherence to guideline-recommended ther-
apies was associated with both increased bleeding and a graded reduction in risk-adjusted in-hospital mortality
across both age groups.
Conclusions In this large population of nonagenarians and centenarians with NSTE-ACS, increasing adherence to guideline-
recommended therapies was associated with decreased mortality. These findings reinforce the importance of
optimizing care patterns for even the oldest patients with NSTE-ACS, while examining novel approaches to re-
duce the risk of bleeding in this rapidly expanding patient population. (J Am Coll Cardiol 2007;49:1790–7)
© 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.01.066d
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ahe elderly are the fastest growing segment of the U.S.
opulation. Whereas other diseases have surpassed heart
isease as the primary cause of death at younger ages, heart
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urham, North Carolina; ‡Pennsylvania Hospital, University of Pennsylvania Health
ystem, Philadelphia, Pennsylvania; §Denver VA Medical Center/University of Colo-
ado, Denver, Colorado; University of Cincinnati College of Medicine, Cincinnati,
hio; and ¶Saint Luke’s Mid America Heart Institute, Kansas City, Missouri.
RUSADE is a National Quality Improvement Initiative of the Duke Clinical
esearch Institute. CRUSADE is funded by the Schering-Plough Corporation
Kenilworth, New Jersey). Bristol-Myers Squibb (New York, New York)/Sanofi
Bridgewater, New Jersey) Pharmaceuticals Partnership provided additional funding
upport. Millennium Pharmaceuticals, Inc. (Cambridge, Massachusetts) also funded
his work.y
Manuscript received July 14, 2006; revised manuscript received January 5, 2007,
ccepted January 5, 2007.isease remains the number one killer of elderly patients (1).
lthough just 2% of the U.S. population is over age 85, this
roup accounts for 30% of all myocardial infarction-related
eaths (2,3). Despite their increasing prevalence and burden
f disease, those of extreme chronological age are often
xcluded from cardiovascular clinical trials, and numbers
ncluded in clinical registries remain low. Therefore, little is
nown about the management and outcomes of acute
oronary syndromes in this subgroup. In particular, there is
ncertainty regarding the risks and benefits of current
reatment guidelines, which have been developed on the basis
f observations from predominantly younger populations (4).
As a result of the changing demographics in the U.S., there
re now sufficient numbers of older elderly patients (age 90
ears) in clinical registries to enable an analysis of this unique
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May 1, 2007:1790–7 Acute Coronary Syndromes in the Older Elderlyubgroup. The CRUSADE (Can Rapid risk stratification of
nstable angina patients Suppress ADverse outcomes with
arly implementation of the American College of Cardiology/
merican Heart Association Guidelines) National Quality
mprovement Initiative is an ongoing, voluntary, observational
ata collection and quality improvement initiative among
atients with non–ST-segment elevation acute coronary syn-
romes (NSTE-ACS) and currently includes more than 5,000
atients age 90 years (the “older elderly”)—representing one
f the largest cohorts of such patients ever assembled (5). In
his study, we used data from CRUSADE to examine con-
emporary treatment and outcomes of NSTE-ACS among the
lder elderly, to compare their treatment and outcomes with
hose of a “younger elderly” cohort (age 75 to 89 years), and to
dentify key clinical features associated with adverse outcomes
mong this understudied population.
ethods
atient population. The population for our study was
erived from the CRUSADE Quality Improvement Initia-
ive. Details of the CRUSADE design and data elements
ave been published previously (5). To be eligible, patients
ust arrive at a participating facility either via the emer-
ency department or by transfer within 24 h of onset of
ymptoms. In addition, their initial evaluation must reveal 1
r more high-risk features including ST-segment depres-
ion, transient ST-segment elevation, or elevated levels of
ardiac biomarkers. The institutional review board at each
ospital approves participation in CRUSADE.
Our analysis included patients age 75 years enrolled in
RUSADE from January 1, 2001, through June 30, 2005.
uring this period, a total of 148,147 patients were enrolled
t 525 hospitals. After excluding 255 patients who were
issing age data and 96,065 patients age 75, the final
opulation for our analysis included 51,827 patients 75
ears old, of whom 5,557 were 90 years old and 112 were
100 years old.
ata collection and definitions. All data were obtained by
etrospective chart review by trained data abstractors using
tandardized case report forms and definitions. Data col-
ected include baseline clinical characteristics, laboratory
esults, use of acute medications (24 h from presentation),
se and timing of invasive cardiac procedures (e.g., coronary
ngiography, percutaneous coronary revascularization, by-
ass surgery), in-hospital clinical outcomes, and discharge
edications and interventions. Contraindications to specific
herapies were also recorded, details of which are contained
n the Appendix.
Post-admission myocardial infarction was defined as
linical signs and symptoms of a new infarction confirmed
y new electrocardiogram (ECG) changes or (re-)elevation
f cardiac biomarkers. Stroke was defined as a new focal
eurologic defect lasting24 h. Heart failure was defined as
xertional dyspnea, orthopnea, rales greater than one-third
f lung fields, elevated jugular venous pressure, or pulmo- wary congestion on chest X-ray
hought to be related to cardiac
ysfunction. Cardiogenic shock
as defined as systolic blood
ressure 90 mm Hg for 1 h
elt to be secondary to cardiac
ysfunction. Major bleeding was
efined as an absolute hematocrit
rop of 12%, intracranial hem-
rrhage, retroperitoneal bleed, red blood cell transfusion in
onjunction with a documented bleeding event if baseline
ematocrit was 28%, or any red blood cell transfusion if
aseline hematocrit was 28%. Any adverse outcome was
efined as post-admission myocardial infarction, cardio-
enic shock, heart failure, stroke, or death.
tatistical analysis. We compared baseline patient charac-
eristics, clinical presentations, in-hospital care patterns, and
n-hospital outcomes between the older elderly population
age 90 years) and a younger elderly (age 75 to 89 years)
ohort. Continuous variables are described as medians and
5th and 75th percentiles, whereas categorical variables are
escribed as frequencies. For binary comparisons, we used
ilcoxon rank sum tests for continuous variables and
hi-square tests were for categorical variables.
Analyses of the association between receipt of 5
uideline-recommended acute therapies (aspirin, beta-
lockers, heparin within 24 h of presentation, performance
f early cardiac catheterization [i.e., within 48 h of presen-
ation], and glycoprotein IIb/IIIa inhibitors for patients
ndergoing early cardiac catheterization) and in-hospital
utcomes were performed based on both the cohort eligible
or at least 1 of the therapies and on the “ideal patient
ohort,” such that patients with 1 or more contraindications
o a therapy were excluded from both the numerator and
enominator of the calculation (6). For each patient in the
opulation eligible for at least 1 of the therapies, we then
alculated an adherence score equal to the number of
herapies received (0 to 5) divided by the number of
herapies the patient was eligible to receive (1 to 5). This
alue was multiplied by 100 to arrive at the percent
dherence score. For these and other analyses of in-hospital
utcomes, we excluded patients with missing outcome data
nd those who were transferred to another hospital before
ischarge.
We also examined the association between major
leeding and receipt of 5 therapies known to be associ-
ted with bleeding (aspirin, heparin, clopidogrel within
4 h, early cardiac catheterization, and administration of
lycoprotein IIb/IIIa inhibitors for patients undergoing
arly catheterization). For these analyses, the dependent
ariable was the number of therapies received (rather than
he proportion of eligible therapies). This approach was
hosen because we felt that the number of cumulative
herapies, rather than proportional adherence, would be
ore closely related to bleeding outcomes. These analyses
Abbreviations
and Acronyms
CI  confidence interval
NSTE-ACS  non–ST-
segment elevation acute
coronary syndromes
OR  odds ratioere performed using both the overall patient population
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Acute Coronary Syndromes in the Older Elderly May 1, 2007:1790–7s well as the “ideal patient cohort” method. For the
nalyses of bleeding complications and transfusion, we
lso excluded patients who underwent coronary artery
ypass surgery during the hospitalization.
To examine the independent association between age
roup (older elderly vs. younger elderly) and each in-
ospital outcome of interest, we used a generalized
stimating equation logistic regression approach to ac-
ount for the effect of potential confounders as well as
ithin-hospital clustering of responses (7). In each case,
ur multivariable model adjusted for the following co-
ariates: female gender, body mass index, race, family
istory of coronary artery disease, hypertension, diabetes,
urrent/recent smoker, hypercholesterolemia, prior myo-
ardial infarction, prior percutaneous coronary interven-
ion, prior coronary artery bypass graft, prior heart
ailure, prior stroke, renal insufficiency, ST-segment
epression, ST-segment elevation, both ST-segment de-
ression and ST-segment elevation, signs of heart failure
t presentation, heart rate, systolic blood pressure, and
ositive cardiac biomarkers.
To investigate the independent relationship between
dherence to recommended therapies and in-hospital mor-
ality, we used adherence score quartile as a categorical
ariable with the lowest quartile as the reference group. For
his analysis, we tested for a linear trend of adherence score
uartile with respect to mortality across age groups and
he interaction effects of adherence score quartile and age
roups. Similar analyses were performed to explore the
elationship between the absolute number of therapies
eceived (as described in the preceding text) and both major
leeding and in-hospital mortality. These analyses were
epeated after excluding those patients who died within 24 h
f admission (because of their reduced opportunity to
eceive the therapies). Because our main findings were not
ltered in these restricted analyses, we report only those
esults from the overall patient population. Additional
nalyses were performed to examine the univariate and
ultivariate associations between receipt of each individual
herapy and in-hospital mortality using the identical gener-
lized estimating equation-based approach to risk adjust-
ent as described in the preceding text.
Finally, we performed a multivariable analysis to identify
hose admission factors independently associated with in-
ospital mortality among the older elderly population.
andidate variables for this analysis include all the baseline
haracteristics listed previously as well as 2-way interaction
ffects. Although several quantitative interactions were
dentified, none of the interactions were qualitative, and
hus the final model excluded these interactions for ease of
nterpretation. A p value 0.05 was considered statistically
ignificant for all tests. All analyses were performed with
AS software version 8.2 (SAS Institute Inc., Cary, North
arolina). Aesults
atient characteristics. Baseline characteristics of the
lder and younger elderly cohorts are described in Table 1.
hile both groups were similar in many respects, the older
lderly (90 years) were more likely to be women and were
ess likely to have traditional coronary artery disease risk
actors including diabetes, recent smoking, obesity (defined
s body mass index 30 kg/m2), and a family history of
remature coronary artery disease (Table 1). There was no
ifference in low-density lipoprotein cholesterol levels, but
he older elderly had lower triglycerides and slightly higher
igh-density lipoprotein cholesterol levels. The older elderly
ere more likely to have renal insufficiency and a history of
eart failure. The prevalence of previous myocardial infarc-
ion did not differ between the 2 groups, but the older
lderly were less likely to have undergone previous percuta-
eous coronary intervention or coronary artery bypass
urgery.
linical presentation and processes of care. There were
nly minor differences in clinical presentation between the
lder and younger elderly (Table 2). The older elderly were
omewhat less likely to have ST-segment depression on
heir presenting ECG but more likely to have elevated
ardiac biomarkers. The older elderly were somewhat more
ikely to have evidence of hemodynamic compromise on
resentation including systolic blood pressure 90 mm Hg,
eart rate 100 beats/min, and signs of heart failure on
hysical exam. The older elderly were less likely to be cared
or by a cardiologist (33.0% vs. 48.0%, p  0.001).
se of guideline-recommended therapies. The propor-
ion of patients with documented contraindications to
uideline-recommended therapies is listed in Table 3.
hile contraindications to aspirin and beta-blockers were
imilar between the older and younger cohorts, the older
lderly more often had documented contraindications to
eparin, clopidogrel, angiotensin-converting enzyme inhib-
tors, statins, and glycoprotein IIb/IIIa inhibitors. Cardiac
atheterization was felt to have been contraindicated twice
s frequently among the older elderly compared with the
ounger elderly (59.8% vs. 26.9%, p  0.001)—most
ommonly due to either “advanced age” (40.6%) and “do-
ot-resuscitate” status (29.3%).
Even among patients without contraindications, the older
lderly were less likely to receive guideline-recommended
cute therapies including heparin (75.1% vs. 82.4%), glyco-
rotein IIb/IIIa inhibitors (12.0% vs. 29.2%), and statins
30.4% vs. 45.7%; all p  0.001) in the first 24 h after
dmission (Table 4). Among patients not receiving statins
efore admission, rates of statin use within 24 h of presen-
ation were 18.7% and 26.7% for the older and younger
lderly cohorts, respectively (p  0.001). Among eligible
atients, only 10.8% of the older elderly compared with
6.3% of the younger elderly underwent cardiac catheter-
zation within the first 48 h after presentation (p  0.001).
ccordingly, the use of revascularization was less frequent
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May 1, 2007:1790–7 Acute Coronary Syndromes in the Older Elderlymong the older versus younger elderly (12.6% vs. 40.1%,
 0.001).
n-hospital outcomes. Compared with the younger el-
erly, the older elderly were more likely to die during the
ospitalization (12.0% vs. 7.8%, p  0.001) and were also
ore likely to experience any adverse cardiovascular out-
ome (26.8% vs. 21.3%, p  0.001) (Table 5). These
ifferences in outcomes persisted after adjustment for po-
ential confounding characteristics with adjusted odds ratios
OR) of 1.23 (95% confidence interval [CI] 1.13 to 1.35) for
ortality and 1.08 (95% CI, 1.00 to 1.15) for any adverse
utcome. However, the adjusted risks of in-hospital stroke
OR 0.61, 95% CI 0.45 to 0.82) and major bleeding (OR
.67, 95% CI 0.58 to 0.78) were lower among the older
lderly (Table 5). The adjusted ORs were generally similar
hen the analysis was restricted to the ideal cohort
Baseline Demographics and Clinical Characteris
Table 1 Baseline Demographics and Clinica
Age >90
(n  5,55
Age (yrs)* 92 (91, 94
Female gender (%) 67.4
White race (%) 86.1
BMI (kg/m2)* 23.4 (20.8, 2
Diabetes mellitus (%) 20.4
Hypertension (%) 73.7
Hyperlipidemia (%) 24.9
Previous stroke (%) 16.5
Obesity (BMI 30 kg/m2) (%) 7.6
Previous MI (%) 33.0
Previous CABG (%) 9.3
Previous PCI (%) 8.7
History of heart failure (%) 39.3
Family history of CAD (%) 14.8
Recent/current smoker (%) 2.5
Previous aspirin use (%) 46.7
Creatinine clearance (ml/min)† 23.9 (18.2, 3
LDL (mg/dl)* 94.0 (71.0, 1
HDL (mg/dl)* 44.0 (35.0, 5
Triglycerides (mg/dl)* 96.0 (69.0, 1
Baseline hematocrit (%)* 37.2 (33.6, 4
Medicare (%) 73.1
HMO/private (%) 25.4
*Presented as median (25th, 75th percentiles); †creatinine clearance
BMI  body mass index; CABG  coronary artery bypass graft; CAD
maintenance organization; LDL  low-density lipoprotein; MI  myoc
resenting Characteristics
Table 2 Presenting Characteristics
Age >90 yrs Age 75–89 yrs p Value
ST-segment depressions (%) 35.0 36.9 0.001
CK-MB positive (%) 74.1 71.1 0.001
CK-MB5 ULN (%) 29.1 31.6 0.001
Troponin positive (%) 86.8 81.8 0.001
Systolic BP90 mm Hg (%) 4.9 4.1 0.004
Heart rate100 beats/min (%) 28.9 25.5 0.001
Signs of heart failure (%) 45.4 33.7 0.001rP  blood pressure; CK-MB  creatine kinase-myocardial band; ULN  upper limit of normal.f patients without documented contraindications to
uideline-recommended care. Despite their higher rate of
dverse outcomes, the older elderly had the same median
ength of stay (5 days) as the younger elderly.
Figure 1 depicts the relationship between adherence to
uideline-recommended therapies and in-hospital mortality
cross both age groups. As the adherence score increased,
he mortality rate declined in a graded fashion (p  0.001
or linear trend) in both groups. At each level of adherence,
owever, mortality was higher among the older elderly
ompared with the younger elderly (p  0.001). There was
o evidence of a significant adherence score–age interaction.
o examine which of the recommended therapies was most
losely associated with reduced mortality, we examined
isk-adjusted mortality according to the specific therapy
eceived among the ideal cohort of both groups (Table 6).
hese analyses demonstrated that acute aspirin, beta-
locker, and catheterization within 48 h were all associated
ith lower adjusted in-hospital mortality. Acute heparin
dministration was not associated with a reduction in
djusted in-hospital mortality, while use of a glycoprotein
Ib/IIIa inhibitor was associated with increased mortality.
Increasing use of therapies with the potential to increase
leeding (acute aspirin, acute clopidogrel, acute heparin,
atheterization within 48 h with or without glycoprotein
Ib/IIIa inhibitors) was associated with a direct, graded
racteristics
Age 75–89 yrs
(n  46,270) p Value
81 (78, 84) 0.001
50.1 0.001
85.7 NS
25.8 (22.9, 29.2) 0.001
34.2 0.001
76.1 0.0001
45.2 0.001
15.8 NS
18.9 0.001
33.7 NS
23.7 0.001
20.1 0.001
26.9 0.001
25.0 0.001
8.8 0.001
49.2 0.001
36.0 (26.0, 47.6) 0.001
93.0 (71.0, 118.0) NS
41.0 (34.0, 51.0) 0.001
109.0 (77.0, 154.0) 0.001
38.3 (34.4, 41.9) 0.001
68.9 0.001
28.7 0.001
ted by the Cockgroft-Gault formula.
onary artery disease; HDL  high-density lipoprotein; HMO  health
farction; PCI  percutaneous coronary intervention.tics
l Cha
yrs
7)
)
6.6)
1.6)
19.0)
4.0)
31.0)
0.7)
calculaelationship with the risk of major bleeding across both age
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Acute Coronary Syndromes in the Older Elderly May 1, 2007:1790–7roups, among those eligible for all 5 therapies (Fig. 2).
his relationship remained highly statistically significant in
nalyses that adjusted for differences in baseline patient
haracteristics (p  0.001 for linear trend).
ultivariable analysis: admission factors associated with
ortality. The results of our multivariable analysis to identify
dmission factors associated with in-hospital mortality are
ummarized in Table 7. Among the older elderly, traditional
oronary disease risk factors (diabetes, renal insufficiency,
besity), acute coronary syndrome severity (troponin ratio), and
ompromised hemodynamics (higher heart rate, lower systolic
lood pressure, signs of heart failure) were each independently
ssociated with increased in-hospital mortality. Prior percuta-
eous coronary intervention and dyslipidemia were associated
ith lower in-hospital mortality.
iscussion
n this study, we used data from the CRUSADE initiative
o investigate the contemporary treatment and outcomes of
STE-ACS among one of the largest cohorts of nonage-
arians and centenarians ever studied. In-hospital outcomes
or the older elderly were poor; 1 in 4 suffered a major
Documented Contraindications to Acute Medica
Table 3 Documented Contraindications to A
Medication
Aspirin (%)
Beta-blockers (%)
Heparin* (%)
Clopidogrel (%)
Angiotensin-converting enzyme inhibitors (%)
Angiotensin receptor blockers (%)
Statin (%)
Glycoprotein IIb/IIIa inhibitors (%)
*Heparin: low-molecular-weight or unfractionated heparin.
n-Hospital Treatments Amongatients Without Contraindications
Table 4 In-Hospital Treatments AmongPatients Without Contraindications
Treatment
Age
>90 yrs
Age
75–89 yrs p Value
Medical therapies within 24 h
of admission
Aspirin (%) 90.6 91.7 0.01
Beta-blockers (%) 80.7 82.2 0.02
Heparin (%)* 75.1 82.4 0.001
Glycoprotein IIb/IIIa inhibitors (%) 12.0 29.2 0.001
Angiotensin-converting enzyme
inhibitors (%)
45.3 47.1 0.03
Clopidogrel (%) 35.5 40.1 0.001
Statins (%) 30.4 45.7 0.001
Coronary interventions
Cardiac catheterization 48 h (%) 10.8 36.3 0.001
PCI 48 h (%) 6.5 20.2 0.001
CABG during hospitalization (%) 1.1 9.4 0.001
Coronary revascularization, any (%) 12.6 40.1 0.001y
Heparin: low-molecular-weight or unfractionated heparin.
CABG  coronary artery bypass grafting; PCI  percutaneous coronary intervention.dverse outcome, and 1 in 8 did not survive to discharge.
lthough the older elderly were less likely than their younger
lderly counterparts to receive guideline-recommended acute
ospital care, there was a strong, graded relationship be-
ween receipt of such therapies and lower in-hospital
ortality. This relationship was observed despite a graded
ncrease in major bleeding among the older elderly associ-
ted with receiving a greater number of antithrombotic and
nvasive interventions.
The American College of Cardiology/American Heart
ssociation Guidelines for the Management of Unstable
ngina and Non–ST-Segment Elevation Myocardial In-
arction recognize that elderly patients are at increased risk
rom coronary revascularization procedures, but nonetheless
uggest that the benefits of aggressive treatment and prompt
evascularization can be extrapolated from clinical trials that
nrolled predominantly younger patients to the older elderly
4). Our findings, which demonstrate a strong, graded
ssociation between adherence to guideline-recommend
herapies and lower in-hospital mortality among both the
ounger and older elderly, support this position. In partic-
lar, we found that use of aspirin, beta-blockers, and early
ardiac catheterization was associated with a marked reduc-
ion in the risk of in-hospital mortality among both groups.
n practice, however, guideline-recommended acute thera-
ies were more likely to be considered “contraindicated”
mong those age 90 years compared with the 75- to
9-year-old cohort.
For several recommended therapies, including early car-
iac catheterization, the most common contraindication
ited was advanced age itself. This category likely represents
comprehensive term that includes a broad range of clinical,
thical, and economic factors that are difficult to discern.
o-not-resuscitate status was the next most common con-
raindication. Do-not-resuscitate status may indicate reluc-
ance on the part of the patient to undergo what are
erceived to be futile life-saving efforts, although code status
hould not preclude optimal medical management (8). In
ontrast, “patient refusal” was more often listed as a contra-
ndication among those age 75 to 89 years, suggesting that
hysicians were more likely to approach even borderline
andidates for coronary revascularization among the
rapies
Medical Therapies
90 yrs Age 75–89 yrs p Value
.0 7.8 0.52
.0 11.1 0.024
.0 8.9 0.001
.3 15.1 0.001
.6 14.6 0.001
.2 8.6 0.001
.9 5.7 0.001
.7 22.4 0.001l The
cute
Age >
10
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23
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16
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40ounger elderly.
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May 1, 2007:1790–7 Acute Coronary Syndromes in the Older ElderlyThe older elderly were less likely to receive statins,
eparin, glycoprotein IIb/IIIa inhibitors, or coronary
evascularization compared with their younger elderly
ounterparts— even among patients without documented
ontraindications to such care. There are several potential
xplanations for the underutilization of guideline-based
herapies among the older elderly. For example, the older
lderly were less likely to be cared for by a cardiologist;
revious studies have documented that patients under the
rimary supervision of a cardiologist are more likely to
ndergo coronary angiography and to receive guideline-
ecommended therapies (9). Alternatively, underuse of an-
ithrombotic therapies including clopidogrel, heparin, and
lycoprotein IIb/IIIa inhibitors may reflect physician con-
ern that even among patients without overt contraindica-
ions, there is a greater risk of bleeding complications
mong the older elderly—an assumption that is supported
In-Hospital Outcomes
Table 5 In-Hospital Outcomes
Outcome Age >90 yrs Age 75–89
Death (%) 12.0 7.8
Myocardial infarction (%) 3.0 3.5
Stroke (%) 0.9 1.2
Heart failure (%) 16.4 12.9
Cardiogenic shock (%) 3.1 3.5
RBC transfusion (%)† 12.8 14.1
Major bleeding (%)† 9.9 13.1
Any adverse outcome (%)‡ 26.8 21.3
*Reference group for adjusted odds ratio is the age 75 to 89 year-o
outcome: post-admission myocardial infarction, cardiogenic shock, he
CI  confidence interval; RBC  red blood cell.
Figure 1 Relationship Between In-Hospital Mortality Across Ea
Guideline-recommended therapies included acute (24 h) aspirin, acute beta-bloc
and receipt of glycoprotein IIb/IIIa inhibitors for patients undergoing early cathetery our data (10). Recent studies suggest that overdosing of
ntithrombotic therapies also may be an important risk
actor for bleeding complications in the elderly, particularly
ecause renal function may be overestimated in such pa-
ients (11). Whether more careful attention to weight and
enal-based dose reductions or alternative antithrombotic
trategies would further improve the safety of care among
he older elderly is not known, however.
We found that, independent of other risk factors and
omorbid conditions, the older elderly were 23% more
ikely to die during their hospitalization compared with
he younger elderly. End-organ dysfunction on admission
e.g., renal insufficiency, heart failure, and hypotension),
s well as diabetes and obesity, were found to be
ndependently associated with in-hospital mortality. In
he future, these admission factors might be used to
evelop risk stratification strategies in prospective studies
Adjusted Odds Ratio
(95% CI)*
Adjusted Odds Ratio (95% CI)
Among the “Ideal Cohort”*
1.23 (1.13–1.35) 1.36 (1.15–1.60)
0.87 (0.75–1.02) 1.08 (0.85–1.37)
0.61 (0.45–0.82) 0.51 (0.29–0.89)
1.07 (0.99–1.16) 1.19 (1.04–1.36)
0.75 (0.64–0.89) 0.85 (0.64–1.13)
0.80 (0.72–0.88) 0.92 (0.78–1.08)
0.67 (0.58–0.78) 0.84 (0.62–1.13)
1.08 (1.00–1.15) 1.17 (1.04–1.32)
p; †excluded patients who underwent bypass surgery; ‡any adverse
ure, stroke, or death.
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lderly patients with NSTE-ACS.
Several limitations must be considered when interpreting
ur findings. Although CRUSADE is community-based
nd broadly representative, patients in this study were
nrolled only if they had chest discomfort and either ECG
hanges or positive cardiac markers. Thus, many older
dults who present with atypical symptoms or with ACS in
he setting of another major medical illness (e.g., pneumo-
ia, hip fracture) were excluded. Although we attempted to
djust for a broad range of potential covariates in our
ultivariate analyses, we cannot discount the possibility of
nmeasured confounding—particularly in the relationship
etween the adherence to guideline-recommended therapies
nd in-hospital mortality. With respect to the elderly, key
dds Ratio of In-Hospital Mortality Accordingo Acute Therapy Received Among Patients Age75 Years
Table 6
Odds Ratio of In-Hospital Mortality According
to Acute Therapy Received Among Patients Age
>75 Years
Acute Therapy
Unadjusted
OR (95% CI)*
Adjusted
OR (95% CI)*
Aspirin 0.57 (0.51–0.64) 0.65 (0.58–0.73)
Beta-blocker 0.61 (0.56–0.67) 0.67 (0.61–0.74)
Heparin† 1.00 (0.91–1.09) 1.06 (0.96–1.17)
Catheterization within 48 h 0.50 (0.46–0.55) 0.70 (0.64–0.77)
Glycoprotein IIb/IIIa inhibitor 1.03 (0.94–1.13) 1.24 (1.12–1.38)
Glycoprotein IIb/IIIa inhibitor and
catheterization within 48 h
0.76 (0.68–0.85) 0.94 (0.84–1.06)
For overall population, excluding those with contraindications or those transferred out; included
nly patients eligible for each therapy listed. †Heparin: low-molecular-weight or unfractionated
eparin.
CI  confidence interval; OR  odds ratio.
Figure 2 Relationship Between the Number of Therapies Provid
In-Hospital Major Bleeding in Each Group, Including O
Therapies considered included acute (24 h) aspirin, acute heparin, acute clopido
IIb/IIIa inhibitors. Patients who were transferred out or who underwent coronary arariables of functional status, cognitive status, financial
onsiderations, and patient preferences (aside from code
tatus) were not recorded. Furthermore, we were unable to
ccount for undocumented contraindications to recom-
ended therapies or for patients transferred to another
ospital. Finally, only in-hospital outcomes were assessed;
urther studies are necessary to document critical
onger-term functional and quality-of-life outcomes of
STE-ACS among the older elderly.
ultivariable Analysis of Admission Featuresssoci ted With In-Hospital Mortality Amonghe Older E derly*
Table 7
Multivariable Analysis of Admission Features
Associated With In-Hospital Mortality Among
the Older Elderly*
Variables
Adjusted OR
(95% CI)
Adjusted
p Value
Systolic BP (per 10 mm Hg drop) 1.19 (1.16–1.23) 0.001
Signs of heart failure 1.76 (1.45–2.15) 0.001
Renal insufficiency 1.48 (1.23–1.78) 0.001
Troponin ratio (truncated at 40)† 1.01 (1.00–1.02) 0.001
Diabetes mellitus 1.38 (1.14–1.67) 0.001
BMI 25 kg/m2 vs. normal BMI‡ 1.30 (1.08–1.57) 0.026
BMI18.5 kg/m2 vs. normal BMI‡ 1.23 (0.89–1.70) —
Heart rate (per 10 beats/min) 1.05 (1.01–1.08) 0.009
Prior PCI 0.63 (0.45–0.90) 0.010
Dyslipidemia 0.78 (0.65–0.95) 0.014
Only characteristics with p value0.05 were included in the adjusted risk model. There were
ignificant quantitative (but not qualitative) interactions between BMI and signs of heart failure as
ell as prior PCI and signs of heart failure. These terms were not included in the final model.
Troponin ratio: measured troponin/upper limit of normal for local assay at each institution.
Normal BMI: 18.5 to 25 kg/m2.
Abbreviations as in Tables 1, 2, and 6.
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n this unselected population of patients with NSTE-ACS,
onagenarians and centenarians were generally similar to
heir younger elderly counterparts in terms of risk factors
nd underlying patient characteristics. Despite these simi-
arities, the older elderly were more likely to have docu-
ented contraindications to acute treatments, less likely to
eceive such care independent of contraindications, and were
ore likely to die in-hospital. Among the older elderly, there
as a graded relationship between the number of therapies
elivered and bleeding complications. Nonetheless, increasing
dherence to guideline-recommended therapies was associated
ith lower in-hospital mortality in both cohorts. These find-
ngs reinforce the importance of optimizing care patterns for
ven the oldest patients with NSTE-ACS while examining
ovel approaches to reduce the risk of bleeding for this rapidly
xpanding patient population.
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APPENDIX
or a list of contraindications to specific therapies,
lease see the online version of this article.
